Moreover, TK-453 exhibited a notable capacity to inhibit protease activities of SHP2WT with an IC50 value of 0.023 nM, outperforming its impact on SHP2-related proteins (SHP2E76K, SHP2PTP) as well as their homologs (SHP1 and PTP1B).293 In an animal model of imiquimod (IMQ)-induced psoriasis, TK-453 demonstrated potential therapeutic effects by ameliorating macrophage inflammation in mice through the inhibition of the IL-23/Th17 axis. This evidence concerns the gene PTPN11 and psoriasis.